Company Overview and News

21
Intercept And NASH: Itching To The Finish Line

2018-09-18 seekingalpha - 3
Ocaliva is a Farnesoid X receptor agonist that positively regulates glucose, lipid and bile homeostasis and was the first FDA approved therapy for primary biliary cirrhosis in over two decades.
ENTA SGYP CELGZ JUNO CNAT CELG SGYPW NVS ABBV ICPT

4
Synergy Pharmaceuticals: Why Does The Company Keep Pushing Its CRG Loan Borrowing Dates?

2018-09-12 seekingalpha - 4
Synergy promised its investors that on or before August 9th it will provide a strategic update.
SGYP SGYPW BHS

23
4
Are Options Traders Betting on a Big Move in Synergy Pharmaceuticals (SGYP) Stock?

2018-08-31 zacks - 3
Investors in Synergy Pharmaceuticals Inc. (SGYP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 18, 2019 $0.50 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
SGYP SCVL SGYPW BIG PAYC

1
Synergy Investment Group Has A New Target: The Shorts

2018-08-29 seekingalpha - 1
Institutional Investors continue to sell Synergy Pharmaceuticals' stock and now only own 39.7% of the stock according to Nasdaq as of the end of Q2.
SGYP SGYPW

3
Synergy Pharmaceuticals: Troy Hamilton Continues To Deliver

2018-08-24 seekingalpha - 2
Wall Street continues to be on a wait-and-see mode as it continues to wait for the conclusion of strategic review.
SGYP CPHRF SGYPW ESRX

4
Achillion Appoints Dr. Steven Zelenkofske as Chief Medical Officer and Further Strengthens Clinical Development Team

2018-08-21 globenewswire - 1
NEW HAVEN, Conn., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Steven Zelenkofske, D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. Dr. Zelenkofske will assume responsibility for the clinical development of Achillion’s oral factor D small molecule portfolio of compounds to treat complement-mediated diseases.
SGYP BSX SGYPW ACHN

5
Synergy Pharmaceuticals Appears To Be Back On Track At Last

2018-08-20 seekingalpha - 2
Synergy has faced the daunting task of commercializing constipation drug Trulance via a risky go-it-alone strategy; initial efforts were ruinously expensive and yielded anemic prescription growth.
SGYP IRWD SGYPW SLUXF

11
Ironwood Pharmaceuticals' Proposed Separation Should Offer A Favorable Outcome For Shareholders

2018-08-17 seekingalpha - 1
Ironwood Pharmaceuticals is a commercial biotechnology company focused on the treatment of gastrointestinal diseases, abdominal pain, and gout.
IRWD SGYP BIIB AGN AZN SGYPW SCMP SNY

7
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

2018-08-14 zacks - 1
On Aug 13, we issued an updated research report on Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) . This biopharmaceutical company, based in Cambridge, MA, is focused on the development and commercialization of treatments primarily addressing gastrointestinal (“GI”) diseases. The company’s sole marketed drug, Linzess, is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (“CIC”).
4503 IRWD SGYP ALPMY AZN AGN ALPMF AZN SGYPW

2
Synergy Has Turned A Corner

2018-08-13 seekingalpha - 2
Before this quarter I had projections for SGYP to run out of money in Q4 2019.
SGYP SGYPW

4
Synergy Pharmaceuticals (SGYP) Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 zacks - 3
Synergy Pharmaceuticals (SGYP - Free Report) just came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.
SGYP KRO CIVI SGYPW SBOW

SGYP: Synergy Pharmaceuticals Stock Analysis and Research Report

2017-09-29 - Asif

Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. The company discovered, are developing and control 100% worldwide rights to its proprietary uroguanylin based GI platform, which includes one commercial product, TRULANCE (plecanatide), and a second product candidate, dolcanatide. TRULANCE (plecanatide) Its first and only commercial product, TRULANCE™, is approved and marketed in the United States (U.S.), under the trademark name TRULANCE™, as a once-daily treatment for adults with chronic idiopathic constipation, or CIC. In clinical trials, TRULANCE helped improve stool consistency and provide more regular bowel movements. TRULANCE is the only prescription medication for CIC that c...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 871639308